Essa Pharma is facing a call to wind down operations. Soleus Capital Management, one of the company’s largest shareholders, ...

When it came to the study’s secondary endpoints of survival, Telix pointed to a median overall survival (OS) rate of 12.4 ...

Glycomine has bagged a $115 million series C round to continue the progress of its lead candidate through phase 2 development for a rare genetic disorder.

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

For the first quarter of this year, J&J’s total sales of $21.9 billion was up 4.2% over the start of 2024, when accounting ...

CenExel is the latest CRO to change ownership hands. Boston-based private equity firm BayPine has acquired a majority stake ...

The Trump administration is freezing more than $2.2 billion in funding to Harvard University after the school defied the ...

The writing is on the wall at Mural Oncology. Responding to clinical data, the biotech is laying off 90% of its employees and ...

Spruce Biosciences has put out new shoots, snapping up rights to a former BioMarin rare disease candidate and outlining plans ...

Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely ...

After acquiring its developer last year, Edwards Lifesciences has now obtained a European approval for what it described as ...

Having picked up a pipeline of oncology drugs as part of a merger last year, NAYA Biosciences is reverting back to its ...